Breast Cancer

The information below is intended for use by health care providers only. Please consult with your health care provider for more information about clinical trials.

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane.

Study Details

  • Study Site/Tumor Location: Breast
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Female
  • Principal Investigator: Dr. Bane
  • Other Physicians who can consent: Sheth, Yanes

Study Contact Information